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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2015, TaiwanBackground: Campylobacter spp. are zoonotic pathogens, however, knowledge about their
presence and antimicrobial resistance in nonhuman primates is limited. Our animal facility
purchased cynomolgus monkeys (Macaca fascicularis) from various Asian countries: China,
Cambodia, Indonesia, the Philippines, and Vietnam.
Methods: Colonization by Campylobacter spp. was investigated in 238 of the monkeys from
2009 to 2012 and antimicrobial susceptibility testing was carried out for these isolates.
Furthermore, we eradicated these pathogens from these monkeys.
Results: Campylobacter spp. were isolated from 47 monkeys from three specific countries:
China, Cambodia, and Indonesia, with respective isolation rates of 15%, 36%, and 67%. Two
monkeys, which were each infected with Campylobacter jejuni and Campylobacter coli,
showed clinical symptoms of diarrhea and bloody feces. In total, 41 isolates of C. coli and
17 isolates of C. jejuni were detected. Antimicrobial susceptibility varied: in the monkeys from
China, erythromycin (ERY)-, tetracycline (TET)-, and ciprofloxacin-resistant C. coli, in the
monkeys from Cambodia, amoxicillin-intermediate, TET- and ciprofloxacin-resistant C. coli
and amoxicillin- and ciprofloxacin-resistant C. jejuni, and in the monkeys from Indonesia,t the 12th Federation of European Laboratory Animal Science Associations, Barcelona, Spain, June
Research Laboratories, Daiichi Sankyo Co., Ltd., 2-58 Hiromachi 1-chome, Shinagawa-ku, Tokyo
daiichisankyo.co.jp (T. Koga).
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+ MODELTable 1 Prevalence of Campylo
Country (place) N
M
China (Pingnan) 5
China (Hainan)
China (Guangxi)
China (unknown) 2
Cambodia (Kampong Thom)a 3
Indonesia (Uma Uma Island)b
Indonesia (others) 2
Philippines
Vietnam 1
Others
Total 16
a Prevalence rates of monkeys fro
b Prevalence rates of monkeys fro
Please cite this article in press as: Ko
monkeys (Macaca fascicularis) and e
10.1016/j.jmii.2014.12.006ciprofloxacin-resistant C. coli and TET- and ciprofloxacin-resistant C. jejuni were common
(>75%). Multiresistant isolates of C. coli were found in monkeys from all countries and multi-
resistant isolates of C. jejuni were found in monkeys from Indonesia. The eradication rate with
azithromycin was comparable to that with gentamicin (GEN) by oral administration, and was
higher than those with amoxicillin-clavulanic acid (AMC) and chloramphenicol (CHL).
Conclusion: From the perspective of zoonosis, we should acknowledge multiresistant Campylo-
bacter spp. isolated from the monkeys as a serious warning.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Animals kept in captivity or bred in semi-free-range out-
door areas may become infected with enteropathogens in
their enclosures.1 Campylobacteriosis is an important
zoonosis throughout the world.2 Thermophilic Campylo-
bacter spp. have been isolated from the intestinal tracts of
a wide variety of animals, including poultry, swine, and
captive and free-range wild animals.3e6 Campylobacter
spp., particularly Campylobacter jejuni and Campylobacter
coli, are recognized as one of the most frequent causes of
acute diarrheal disease in humans.7
In recent years, concern about this pathogen has
increased mainly because of the frequent isolation of
antimicrobial-resistant isolates in humans and animals8 in
both developed and developing countries, particularly with
regard to the rapid emergence of fluoroquinolone-resistant
and multidrug-resistant Campylobacter spp. Antimicrobial
resistance in both medicine and agriculture is recognized by
the World Health Organization (WHO), along with other
various national authorities, as a major emerging public
health concern. It represents a significant challenge of
global dimensions to human and veterinary medicines with
the prospect of therapeutic failure for life-saving treat-
ments now a reality.bacter spp. in monkeys from di
o. of monkeys Campylo
positive no
ale Female Male
3 29 5
6 0 0
5 0 0
1 5 0
6 0 13
0 33 0
9 1 0
1 5 0
1 2 0
1 0 0
3 75 18
m Cambodia were significantly hi
m Indonesia were significantly hig
ga T, et al., Antimicrobial resistan
radication regimens, Journal of MWhen cynomolgus monkeys (Macaca fascicularis) were
introduced to our animal facility, or were checked during
semi-annual health monitoring, or when abnormal gastro-
intestinal symptoms such as diarrhea and loose stool
occurred, we checked the monkeys for the presence of
Campylobacter spp. from 2009 to 2012 and eradicated them
for the following reason: some research showed that
Campylobacter spp. were linked to gastroenteritis in
nonhuman primates.9e11 Infected monkeys are potential
reservoirs if they are asymptomatic, and they become po-
tential transmitters of Campylobacter spp. to noninfected
monkeys and humans who have had contact with them.12
Moreover, infected monkeys might jeopardize the inter-
pretation of experimental results.13
This study was conducted to determine the prevalence
and the antimicrobial resistance of Campylobacter spp. and
to eradicate them from cynomolgus monkeys.Material and methods
Sample collection
Two hundred and thirty-eight cynomolgus monkeys were
used in this study (Table 1). These monkeys were bred in afferent countries of origin
bacter spp.
. of monkeys
No. of Campylobacter spp. Prevalence
rate (%)
Female C. coli C. jejuni
7 10 2 15
0 0 0 0
0 0 0 0
0 0 0 0
0 9 6 36
22 22 9 67
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
29 41 17 0
gher than those from China (Pingnan).
her than those from China (Pingnan) and Cambodia.
ce in Campylobacter coli and Campylobacter jejuni in cynomolgus
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
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+ MODELconventional and antimicrobial-free production system.
They were fed a commercial diet (PS-A; Oriental Yeast Co.,
Ltd., Tokyo, Japan). Basically, no antibiotics were admin-
istered to them unless they were infected with bacteria and
they needed the administration of antibiotic prophylaxis
based on veterinary checking or symptoms. The numbers of
monkeys which were introduced to our animal facility in
2009, 2010, 2011, and 2012 were 21, 27, 33, and 82,
respectively, and 75 monkeys were bred prior to 2009. Most
of the monkeys were purchased from Hamri Co., Ltd.
(Ibaragi, Japan) and Shin Nippon Biomedical Laboratories
Ltd. (Kagoshima, Japan). These breeders were imported
from China (Pingnan, Hainan, Guangxi), Cambodia
(Kampong Thom), Indonesia (Uma Uma Island), Indonesia
(others), the Philippines, and Vietnam. The monkeys from
Indonesia (Uma Uma Island) were transferred and bred in
Japan (Kagoshima). In our animal facility, monkeys were
housed indoors individually in standard nonhuman primate
caging during quarantine and experiments. The tempera-
ture in the animal rooms was maintained at 26C with a
humidity of 45%. When the sample was collected the
monkeys were aged from 2.7 years to about 20 years.
Isolation and identification of Campylobacter spp.
Fecal samples were collected when each monkey was
introduced to our animal facility, when the monkey showed
diarrhea or loose stool, and when they were checked during
semi-annual health monitoring. The fresh feces were
placed into Petri dishes and transported to the laboratory
within 2 hours of collection. All samples in this study were
plated directly on heart infusion agar (Difco Laboratories,
Detroit, MI, USA) containing 10% defibrinated sheep blood
(Nippon Bio-Test Laboratories, Inc., Tokyo, Japan) and
Campylobacter selective supplement (Oxoid, Hampshire,
England) for primary isolation. The plates were incubated
in a 10% CO2 incubator at 42
C for 36e48 hours. One to
three presumptive Campylobacter colonies were selected
for further identification by using API-Campy (BioMerieux,
Marcy I’Etoile, France) kits and polymerase chain reaction
(PCR) as previously described.14 All of the isolates were
stored in 10% milk at 80C until required for further use.
Eradication regimens
After confirmation, theantibiotic disks (KBDiskEiken:Tokyo,
Japan) used in this study for drug resistance screening were
as follows: amoxicillin-clavulanic acid (AMC; 20:10 mg),
tetracycline (TET; 30 mg), chloramphenicol (CHL; 30 mg),
gentamicin (GEN; 10 mg), erythromycin (ERY; 15 mg), and
ofloxacin (5 mg). AMC (GlaxoSmithKline K.K., Tokyo, Japan),
azithromycin (Pfizer Japan Inc., Tokyo, Japan), CHL (Sigma,
St. Louis,MO,USA), andGEN (WakoPureChemical Industries,
Ltd., Osaka, Japan) were used for eradication regimens.
After a drug screening test for the isolates, themonkeyswere
administered susceptible antimicrobials as follows: AMC at a
dose of 50 mg/kg b.i.d. or 100 mg/kg b.i.d. for 5 days, azi-
thromycin at a dose of 10 mg/kg q.d. or 20 mg/kg q.d. for 3
days, CHL at a dose of 15mg/kg b.i.d. or 20mg/kg b.i.d. for 5
days, or GEN at a dose of 17 mg/kg q.d., 25 mg/kg q.d.,
50 mg/kg q.d., or 100 mg/kg q.d. for 5 days. Basically,Please cite this article in press as: Koga T, et al., Antimicrobial resistan
monkeys (Macaca fascicularis) and eradication regimens, Journal of M
10.1016/j.jmii.2014.12.006azithromycin was administered to the monkeys which were
infectedwith an ERY-susceptible isolate first, and AMC, GEN,
orCHLwas administered to themonkeyswhichwere infected
with an ERY-resistant isolate in the light of their suscepti-
bility. Each antibiotic was administered in a solution of 5%
methyl cellulose (1.0 mL/kg), followed by an additional
1.0 mL of the same solution to rinse the tube. After 2 weeks
and 3 weeks of treatment, the feces were collected and
checked for the presence of Campylobacter spp. Clearance
was defined as the disappearance of the original isolates and
eradication was defined as the disappearance of Campylo-
bacter spp. both 2 weeks and 3 weeks after treatment. All
experimental procedures were performed in accordance
with the in-house guidelines of the Institutional Animal Care
and Use Committee of Daiichi Sankyo Co., Ltd., Tokyo Japan.
Antimicrobial susceptibility testing and
b-lactamase detection
The standard agar dilution method described by the Clinical
and Laboratory Standards Institute (CLSI) was used to
determine the minimal inhibition concentration (MIC) for
Campylobacter spp.15 The following is a list of antimicro-
bials with their abbreviations: amoxicillin (AMX), AMC, TET,
CHL, GEN, amikacin (AMK), tobramycin (TOB), streptomycin
(STR), neomycin (NEO), kanamycin (KAN), spectinomycin
(SPT), ERY, and ciprofloxacin (CIP). All of the antimicrobials
were purchased from Sigma except for clavulanic acid
(Wako Pure Chemical Industries, Ltd.), TET (Tokyo Chemi-
cal Industry Co., Ltd., Tokyo, Japan), GEN (Wako Pure
Chemical Industries, Ltd.), and AMK (Wako Pure Chemical
Industries, Ltd.). For C. coli and C. jejuni, CLSI breakpoints
were available only for TET, ERY, and CIP.15 The CLSI
breakpoints for the Enterobacteriaceae family were used
for the other antimicrobials (AMX, AMC, AMK, STR, and KAN)
except for TOB.16 The National Antimicrobial Resistance
Monitoring System (NARMS) breakpoints were used when
CLSI breakpoints were not available (CHL and GEN).17 The
breakpoint for TOB with Pseudomonas aeruginosa was
adopted.18 The CLSI breakpoint for Neisseria gonorrhea was
used for SPT.16 Since there were no CLSI and NARMS
breakpoints for NEO, we used the breakpoint for Escher-
ichia coli, which is 32 mg/mL.19 The breakpoints used for
each antimicrobial are shown in Supplementary table. A
Campylobacter isolate simultaneously resistant to three or
more different classes of antimicrobials (AMX, TET, CHL,
GEN, ERY, and CIP) was defined as a multidrug-resistant
isolate. C. jejuni ATCC 33560 was used as the quality con-
trol strain. The plates were incubated at 35C for 48 hours
in a microaerobic atmosphere (AneroPak, Mitsubishi Gas
Chemical Company, Inc., Tokyo, Japan) in an incubator.
The MIC was defined as the lowest concentration of a drug
at which no visible growth could be seen. To investigate the
role of the b-lactamase in resistance to AMX, production of
b-lactamase was identified by cefinase disks (Becton Dick-
inson and Company, Sparks, MD, USA).
Statistical analysis
Prevalence rates were analyzed by the Chi-square test for
statistical analysis. The Bonferroni correction method wasce in Campylobacter coli and Campylobacter jejuni in cynomolgus
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
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+ MODELused for multiple comparisons. The p values <0.05 were
considered statistically significant.
Results
Campylobacter spp. prevalence
Campylobacter spp. were isolated from 47 monkeys in
China (Pingnan), Cambodia (Kampong Thom), and Indonesia
(Uma Uma Island; Table 1). Prevalence rates of those from
China, Cambodia, and Indonesia were 15%, 36%, and 67%,
respectively. Prevalence rates of those from Indonesia were
significantly higher than those from China (p < 0.0001) and
Cambodia (p Z 0.0336), and those from Cambodia were
significantly higher than those from China (p Z 0.0258). C.
jejuni and C. coli were found in two monkeys from China
through semi-annual health monitoring. C. jejuni was found
in a monkey from Cambodia which showed diarrhea and C.
coli was found in the monkey from China which showed
bloody feces. Campylobacter spp. were detected in the
other 43 monkeys during the quarantine period. In the
monkeys from China, the birth years of the positive mon-
keys were from 2005 to 2007, except for one monkey, with
a birth year of 2003, and the range of the birth years was
from 1998 to 2008. In the monkeys from Cambodia and
Indonesia, the range of the birth years of the positive
monkeys was from 2007 to 2008, the same as that of the
birth years used for this study. Fifty-eight Campylobacter
spp. were detected and 41 isolates of C. coli and 17 isolates
of C. jejuni were identified (Table 1). In the monkeys from
China, each isolate of C. coli and C. jejuni was isolated
from each monkey. In the monkeys from Cambodia, both C.
coli and C. jejuni were isolated from a monkey at the first
isolation and two isolates of C. coli were recovered at the
first isolation and after administration of the antimicrobial
from a monkey. In the monkeys from Indonesia, two isolates
of C. coli were isolated from a monkey at the first isolation
and the monkey remained colonized with another isolate of
C. coli. C. coli and C. jejuni were isolated at the first
isolation and after administration of the antimicrobial from
three monkeys. Two isolates of C. coli and one isolate of C.
jejuni, and one isolate of C. coli and two isolates of C.
jejuni were isolated at the first isolation and after admin-
istration of the antimicrobial from two monkeys.
Antimicrobial resistance of the Campylobacter spp.
isolates
The MICs of TET, GEN, ERY, and CIP against C. jejuni ATCC
33560 were within the acceptable ranges. The resistance
rates of antimicrobial agents for Campylobacter spp. are
shown in Table 2. The drug resistance patterns of the
Campylobacter spp. are shown in Table 3. The MICs and b-
lactamase production of multiresistant isolates are shown in
Table 4. In the monkeys from China, no AMX-, AMC-, and
CHL-resistant Campylobacter spp. were observed. TET-
resistant, CIP-resistant, and ERY-resistant C. coli were
common (80%). GEN-resistant C. coli showed TET, AMK,
TOB, STR, NEO, KAN, SPT, and CIP resistance (Table 4:
H229). One of two isolates of C. jejuni showed susceptibility
to all antimicrobials used in this study, and another isolatePlease cite this article in press as: Koga T, et al., Antimicrobial resistance in Campylobacter coli and Campylobacter jejuni in cynomolgus
monkeys (Macaca fascicularis) and eradication regimens, Journal of Microbiology, Immunology and Infection (2015), http://dx.doi.org/
10.1016/j.jmii.2014.12.006
Table 3 Drug resistance patterns of the Campylobacter spp. isolates
Campylobacter spp. No. of resistant agents Antimicrobial resistance patterns No. of isolates
C. coli in China 2 TET, CIP 1
3 TET, CIP, ERY 6
4 TET, GEN, CIP, ERY 2
C. coli in Cambodia 2 TET, CIP 3
2 AMX, CIP 1
3 TET, GEN, CIP 4
C. coli in Indonesia 2 TET, CIP 5
3 TET, CIP, ERY 7
5 AMX, TET, CHL, GEN, CIP 1
C. jejuni in Cambodia 2 TET, CIP 1
2 AMX, CIP 5
C. jejuni in Indonesia 2 TET, CIP 6
4 TET, GEN, CIP, ERY 3
AMX Z amoxicillin; CHL Z chloramphenicol; CIP Z ciprofloxacin; ERY Z erythromycin; GEN Z gentamicin; TET Z tetracycline.
Table 4 Minimal inhibition concentrations (MICs) of 13 antimicrobial agents for multiresistant Campylobacter spp. and b-
lactamase production
Isolate number b-lac AMX AMC TET CHL AMK GEN KAN NEO SPT STR TOB ERY CIP
Campylobacter coli in China H212 e 2 2 >128 4 16 0.5 >128 >128 >128 >128 4 >128 32
H229 e 2 2 >128 8 128 >128 >128 >128 >128 >128 >128 >128 64
C. coli in Cambodia H468 þ 16 8 >128 16 64 >128 >128 4 16 128 >128 8 128
C. coli in Indonesia H499 e 1 1 >128 4 64 1 >128 >128 >128 2 8 >128 16
H501 þ >128 16 >128 64 64 >128 >128 >128 >128 >128 >128 4 64
Campylobacter jejuni in Indonesia H503 e 2 1 >128 16 64 >128 >128 >128 4 4 >128 >128 >128
AMC Z amoxicillin-clavulanic acid; AMK Z amikacin; AMX Z amoxicillin; b-lac Z b-lactamase; CHL Z chloramphenicol;
CIP Z ciprofloxacin; ERY Z erythromycin; GEN Z gentamicin; KAN Z kanamycin; NEO Z neomycin; SPT Z spectinomycin;
STR Z streptomycin; TET Z tetracycline; TOB Z tobramycin.
Table 5 Clearance and eradication rates of Campylobacter spp. in each regimen
Regimens Clearance ratea Eradication rateb
Amoxicillin-clavulanic acid 50e100 mg/kg b.i.d. for 5 d 14/15 (93) 10/15 (67)
Azithromycin 10e20 mg/kg q.d. for 3 d 26/29 (90) 24/29 (83)
Chloramphenicol 15e20 mg/kg b.i.d. for 5 d 6/8 (75) 4/8 (50)
Gentamicin 17e25 mg/kg q.d. for 5 d 2/4 (50) 1/4 (25)
Gentamicin 50e100 mg/kg q.d. for 5 d 5/5 (100) 4/5 (80)
a Clearance was defined as the disappearance of the original isolates and eradication was defined as the disappearance of
Campylobacter spp. both 2 weeks and 3 weeks after treatment.
b Three monkeys were not eradicated because of the urgent needs for the experiments.
Data are presented as n/N (%).
Antimicrobial resistance in Campylobacter spp. 5
+ MODELshowed only CIP-resistance. In the monkeys from Cambodia,
no AMC-, CHL-, NEO-, SPT-, or ERY-resistant Campylobacter
spp. were observed. TET-resistant and CIP-resistant C. coli
were common (>75%). GEN-resistant C. coli showed TET,
AMK, TOB, STR, KAN, and CIP resistance (Table 4: H468). One
AMX-resistant isolate of C. coli was observed (Table 2). By
contrast, AMX-resistant and CIP-resistant C. jejuni were
common (>80%). In the monkeys from Indonesia, no AMC-
resistant Campylobacter spp. were observed. CIP-resistant
C. coli were common (Table 2). ERY-resistant C. coli
showed AMK, NEO, KAN, and SPT resistance (Table 4: H499).Please cite this article in press as: Koga T, et al., Antimicrobial resistan
monkeys (Macaca fascicularis) and eradication regimens, Journal of M
10.1016/j.jmii.2014.12.006One isolate of C. coli was resistant to AMX, TET, CHL, GEN,
AMK, TOB, STR, NEO, KAN, SPT, and CIP (Table 4: H501). By
contrast, all C. jejuni isolated from the monkeys from
Indonesia were TET-resistant and CIP-resistant (Table 2).
GEN-resistant C. jejuni showed TET, AMK, TOB, NEO, KAN,
ERY, and CIP resistance (Table 4: H503). Campylobacter
spp., for which the MIC for AMX was >4 mg/mL, produced b-
lactamase in the monkeys from all three countries (24 iso-
lates). Multiresistant isolates of C. coli were found in the
monkeys from all three countries and those of C. jejuniwere
found in the monkeys from Indonesia (Table 3).ce in Campylobacter coli and Campylobacter jejuni in cynomolgus
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
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The clearance and eradication rates in each regimen are
shown in Table 5. The eradication rate of azithromycin was
comparable to that of GEN by oral administration at doses
of 50 mg/kg or 100 mg/kg, and higher than those of AMC
and CHL. Among the eradication failures in five monkeys
treated with azithromycin, ERY-resistant C. jejuni
(MIC > 128 mg/mL) appeared in two monkeys after the
treatment and two C. coli isolates with an MIC of 8 mg/mL
for ERY were still colonized. In the eradication failure in a
monkey at higher doses (50 mg/kg and 100 mg/kg) of GEN
treatments, an isolate with the same MIC for GEN
appeared. Among the eradication failures in three monkeys
at lower doses (17 mg/kg or 25 mg/kg) of GEN, a GEN-
resistant isolate (MIC > 128 mg/mL) appeared in a monkey
after the treatment. Among the eradication failures in five
monkeys treated with AMC, three isolates with higher MICs
and an isolate with a lower MIC for AMC appeared, however,
all isolates were susceptible to AMC. Among the eradication
failures in four monkeys treated with CHL, two isolates with
the same or lower MIC for CHL appeared. Most of the
monkeys administered AMC and GEN showed soft feces
during the treatment.Discussion
Campylobacter spp. were isolated from three specific pla-
ces: China (Pingnan), Cambodia (Kampong Thom), and
Indonesia (Uma Uma Island). Interestingly, no Campylo-
bacter spp. were isolated from other places even in the
same country. The monkeys from China and Cambodia were
bred in semi-free-range areas and the monkeys from
Indonesia were bred in free-range areas. A higher per-
centage of the prevalence rate of the monkeys from
Indonesia is attributed to the free-range environment. In
semi-free-range areas, disinfected water and food washed
with disinfected water were provided. Although contami-
nated water and food do not currently serve as a source of
infection in the semi-free-range areas, there is a possibility
of the origin of infection prior to disinfecting the food and
water. In broiler flocks, horizontal transmission from the
surrounding environment either via the farm workers or
other vectors such as wild birds, vermin, and house flies, is
considered to be the most likely source of con-
tamination.20e22 This contamination by the environment is
also a potential origin of infection of the monkeys. Molec-
ular epidemiological studies are needed to clarify this.
C. coli was the predominant species from the monkeys in
all specific countries in this study. This finding is consistent
with a previous report that the prevalence of C. coli was
two times higher than that of C. jejuni in laboratory pri-
mates,23 although there are few reports about the preva-
lence of Campylobacter spp. two monkeys which were
infected with C. jejuni and C. coli showed clinical symp-
toms such as diarrhea and bloody feces, respectively; these
monkeys were aged 4 years and 5 years. The other 45
monkeys did not show any clinical symptoms. These results
suggested that cynomolgus monkeys at an age of >2.6 years
old would be asymptomatic carriers of the Campylobacter
spp. infection.Please cite this article in press as: Koga T, et al., Antimicrobial resistan
monkeys (Macaca fascicularis) and eradication regimens, Journal of M
10.1016/j.jmii.2014.12.006Antibiotic resistance with the fluoroquinolones and
macrolide antibiotics has now emerged globally in
Campylobacter spp.8 and some of the resistant isolates
have been reported to spread from animals to humans via
the food chain.24 Since most of the monkeys have not been
exposed to antibiotics, the antibiotic resistant Campylo-
bacter spp. are supposed to have been introduced from the
surrounding environment. There were differences in resis-
tant rates among the three sources, presumably reflecting
differences in antibiotic use and practice. Campylobacter
spp. are increasingly resistant to clinically important anti-
biotics for humans, since they are exposed to antibiotics
used in both animal production and human medicine. The
patterns of emerging resistance to the antimicrobial agents
useful in treatment of the disease were compared in three
countries. Some aminoglycosides, such as NEO and KAN, are
only or often used for the animal production in some
countries25 and several aminoglycoside resistance genes
have been reported.8 Seven aminoglycosides were exam-
ined. In the monkeys from China, CIP-resistant, ERY-resis-
tant, and TET-resistant C. coli were very common. In
China, fluoroquinolones were used in poultry production;
TET and macrolides, especially tylosin, were used as feed
additives and prophylactic agents in conventional pig
farms.6 Several aminoglycoside agents, such as NEO, KAN,
and SPT-resistant C. coli were common. This antibiotic
resistance might be attributed to the sources of these an-
imals. Only limited information is available on the preva-
lence and antimicrobial resistance of Campylobacter spp.
from humans and animals in Cambodia and Indonesia.5,26 In
the monkeys from Cambodia, CIP-resistant and TET-
resistant C. coli and AMX-resistant and CIP-resistant C.
jejuni were common. Monitoring the retail poultry in
Phnom Penh, Cambodia showed that C. coli were sensitive
to AMX, ERY, and azithromycin and that C. jejuni were also
sensitive to GEN.5 In a similar fashion, C. coli were sensitive
to ERY and C. jejuni were sensitive to GEN, however, the
susceptibility rate of AMX was different. In the monkeys
from Indonesia, CIP-resistant and TET-resistant Campylo-
bacter spp. were common. Ampicillin-resistant, CIP-resis-
tant, and TET-resistant C. jejuni associated with diarrheal
patients have been reported in Indonesia.26 When
comparing the three countries, C. coli isolated from China
were mostly resistant to KAN, NEO, and SPT, which were
categorized in aminoglycoside groups and ERY and
Campylobacter spp. isolated from Cambodia were mostly
resistant to AMX. By contrast, the antimicrobial resistant
rate (>1 drug) of C. coli isolated from Indonesia was the
lowest (59%, Table 3), however, at least one isolate was
resistant to all classes of antibiotics tested in this study. A
surveillance program for antibiotic resistance in Campylo-
bacter spp. from humans and animals in these countries, as
well as the molecular mechanisms of antimicrobial resis-
tance, is needed.
Molecular typing techniques are used to characterize the
variability of an organism.27 These techniques can also
examine the relationship genotyping and antibiotic resis-
tance in epidemiological studies. Pulsed-field gel electro-
phoresis fingerprinting and multilocus sequence typing
would facilitate major contributions to the understanding
of the epidemiology of these bacteria. Further molecular
analysis for epidemiological studies is needed.ce in Campylobacter coli and Campylobacter jejuni in cynomolgus
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bacter spp. from nonhuman primates.28 CIP was effective in
eradicating Campylobacter spp. of marmosets, however,
treatment with either ERY or tylosin failed to eradicate
Campylobacter spp. For clinical therapy of campylobacter-
iosis in humans, macrolides and fluoroquinolones are the
antimicrobial agents of choice and tetracyclines have been
suggested as an alternative choice.29 Intravenous amino-
glycoside therapy may also be considered in more serious
cases of Campylobacter infections, such as bacteremia and
other systemic infections.30 It has been reported that azi-
thromycin is clinically superior to the ERY regimen.31 For the
reasons set forth above, we first treated each monkey with
azithromycin, when Campylobacter spp. were susceptible
to ERY in a drug screening test. We applied the other drugs of
choice by reference to therapy of campylobacteriosis in the
clinical setting for humans. The eradication rate of azi-
thromycin was comparable to that of GEN by oral adminis-
tration at doses of 50 mg/kg or 100 mg/kg, and higher than
those of AMC and CHL. Since treatment failure of azi-
thromycin against ERY-intermediate low (MIC, 8 mg/mL) C.
coli was observed, more doses of azithromycin or other
drugs would be administered to the monkeys. When
Campylobacter spp. were resistant to ERY and they were
susceptible to AMC, GEN, or CHL, we treated the infected
monkey with AMC, GEN, or CHL. In this study, since no sys-
temic infection of monkeys was observed, oral administra-
tion of GEN was attempted. Most of the monkeys at doses of
50 mg/kg or 100 mg/kg showed soft feces, however, a higher
percentage of eradication was observed. It is suggested that
oral administration of GEN is one of the treatment regimens
for GEN-susceptible Campylobacter spp. infection of mon-
keys. We administered relatively higher doses of AMC to the
monkeys, however, the eradication rate was 80%. These
doses would be optimal for eradication in the monkeys.
The Federation of European Laboratory Animal Science
Association working group on nonhuman primate health
reported that C. jejuni was classified as Group 2, which
concerns agents that can cause human disease, but are
unlikely to spread to the community, for which effective
treatment is available.32 They concluded the possibility
that in shipments of monkeys, carriers of infectious agents
transmissible to humans may be present and need to be
taken into account. Since it is not easy to eradicate the
antimicrobial-resistant Campylobacter spp. in cases of
infection, we need to consider that such a risk is reduced to
a sufficiently low level, such as the surveillance of the
animal facility and the eradication of these pathogens.
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